Rubicatin/Rubitidine medical insurance reimbursement policy and ratio

Lurbinectedin is a new alkylating agent widely used in the treatment of malignant tumors such as small cell lung cancer (SCLC). As an innovative drug, rubitidine has shown good efficacy in the treatment of advanced small cell lung cancer, especially in patients who have failed previous treatments. Although the efficacy of rubitidine is recognized, in the Chinese market, rubitidine is not currently covered by medical insurance, which results in its patients having to bear higher treatment costs.

At present, the original drug of rubitidine is already on the market in China, and patients can obtain it through prescription in hospitals. However, since the drug is not included in the national medical insurance catalog, patients often face higher drug costs when purchasing it, especially for cancer patients who require long-term treatment, which imposes a heavy financial burden. According to the situation of the drug market, the price of rupitidine is relatively expensive, and drug prices vary greatly in different regions. Therefore, patients need to pay attention to the proportion of medical insurance and non-medical insurance payment when using this drug.

Although rupitidine is not currently included in medical insurance, in recent years, with the gradual advancement of innovative drugs in the domestic market, the medical insurance reimbursement policies for many new drugs have gradually improved. Therefore, the industry is optimistic about whether rupitidine can be included in the medical insurance catalog, and hopes to apply for inclusion in the medical insurance in the future so that more patients can obtain this effective treatment drug. The specific medical insurance reimbursement ratio and inclusion time point need to be further followed up according to the approval procedures of the National Medical Insurance Administration and relevant drug review agencies.

In China, medical insurance coverage widely affects the popularity of drugs and the financial burden of patients. Therefore, many patients and doctors are looking forward to rubitidine being included in medical insurance in the future and reducing treatment costs. In the future, as competition in the drug market intensifies and patient demand increases, the medical insurance policy for rubitidine may be gradually improved and more drug choices will be provided for patients.

Reference materials:https://www.zepzelca.com/